Non-injectable Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

Description

The global Non-Injectable Insulin Market is witnessing a major transformation with the rising demand for innovative diabetes management solutions. As patients seek more convenient and non-invasive insulin delivery methods, pharmaceutical advancements are accelerating the adoption of non-injectable insulin options. Forecasts indicate substantial growth, driven by increasing diabetes prevalence and continuous innovation in drug formulations and delivery technologies.

Market Insights

The non-injectable insulin market is expected to experience robust expansion over the forecast period. The market is projected to reach $1.46 billion in 2025 and further expand to $2.56 billion by 2032, growing at a CAGR of 8.30%. This growth is attributed to increasing patient preference for non-invasive diabetes treatment methods, improved bioavailability of insulin formulations, and supportive healthcare policies worldwide.

Key Market Drivers

1. Rising Prevalence of Diabetes:

The global diabetes burden is increasing, leading to higher demand for alternative insulin delivery methods. Non-injectable insulin formulations reduce patient discomfort and improve compliance, making them a preferred choice.

2. Technological Advancements in Drug Formulations and Delivery Systems:

Innovations in oral and inhalable insulin delivery enhance bioavailability and patient adherence. Smart insulin delivery devices are revolutionizing diabetes care by providing real-time monitoring and automated dosage adjustments.

3. Regulatory Support and Patient-Centric Solutions:

Supportive healthcare policies and evolving regulatory Analysiss are facilitating the approval and commercialization of non-injectable insulin therapies. Efforts to improve accessibility and affordability are further driving market expansion.

Business Opportunities

1. Expanding Therapeutic Indications:

Beyond traditional diabetes management, non-injectable insulin is being explored for conditions such as metabolic disorders and gestational diabetes. This expansion presents significant opportunities for pharmaceutical companies to diversify their portfolios.

2. E-Commerce Growth and Direct-to-Consumer Sales:

Online pharmacy platforms are gaining traction, allowing patients to access non-injectable insulin more conveniently. The rise of telemedicine further supports the growth of direct-to-consumer sales channels.

3. Strategic Partnerships and Mergers:

Pharmaceutical companies are forming collaborations to accelerate research and development in non-injectable insulin technologies. Joint ventures and acquisitions are enhancing market penetration and competitive advantage.

Regional Analysis

1. Europe: A Leading Market for Non-Injectable Insulin

Europe dominates the non-injectable insulin market, attributed to a strong regulatory framework, high healthcare awareness, and advanced healthcare infrastructure. The European Medicines Agency's proactive approach ensures faster approvals and commercialization of innovative insulin formulations.

2. South Asia & Pacific: Fastest-Growing Market

The increasing diabetes burden in countries like India and China is driving the demand for alternative insulin delivery methods. Rising healthcare awareness and government initiatives promoting diabetes management contribute to market growth.

3. North America: Strong Market Presence

North America remains a key market due to a high prevalence of diabetes, technological advancements, and increasing investment in pharmaceutical research. The region's well-established e-commerce and telehealth services further enhance accessibility to non-injectable insulin products.

Key Players & Competitive Analysis

Several pharmaceutical companies are actively involved in research and development to improve non-injectable insulin formulations. The major players in the market include:

Novo Nordisk

Sanofi

Eli Lilly

MannKind Corporation

Biocon

Janssen Pharmaceuticals

Adocia

Oramed Pharmaceuticals

Dance Biopharm

Medtronic

Key Recent Developments

1. Oramed Pharmaceuticals & Hefei Tianhui Biotech Joint Venture (August 2023)

Oramed Pharmaceuticals partnered with Hefei Tianhui Biotech (HTIT) to advance oral drug products. The joint venture focuses on developing oral insulin formulations and expanding non-injectable insulin technology globally. Market Impact: Strengthens the presence of oral insulin formulations, paving the way for further advancements in non-injectable insulin delivery.

2. Launch of Ozulin by NiedlFree Technologies (November 2023)

NiedlFree Technologies introduced Ozulin, an oral insulin spray for Type 1 and Type 2 diabetes patients. The product is expected to be available globally, including in India, by 2025 or 2026. Market Impact: This innovation is set to disrupt the non-injectable insulin Analysis, offering an alternative that enhances patient convenience and compliance.

Strategic Outlook & Future Trends

1. Emphasis on Personalized Insulin Delivery:

The market is shifting towards customized insulin therapies, integrating smart devices for better glycemic control. AI-driven monitoring and digital health solutions will drive advancements in this sector.

2. Sustainability & Cost-Effective Formulations:

Companies are investing in eco-friendly and cost-efficient insulin delivery solutions to cater to global demand. Reducing production costs while maintaining efficacy remains a key focus.

3. Regulatory Approvals & Market Expansion:

As regulatory bodies streamline approval processes, more players are expected to enter the non-injectable insulin space. Expanding market presence in emerging economies will be a game-changer for industry leaders.

Market Segmentation

1. By Product Type:

Pills Sprays Others

2. By Distribution Channel:

Hospital Pharmacies Online Stores Drug Stores

3. By Region:

North America Europe Asia Pacific Latin America Middle East & Africa

1. Executive Summary

1.1. Global Non-injectable Insulin Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Price Analysis, 2024

3.1. Global Average Price Analysis, by Product Type, US$ Per Unit, 2024
3.2. Prominent Factor Affecting Non-injectable Insulin Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Non-injectable Insulin Market Outlook, 2019 - 2032

4.1. Global Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.1.1. Key Highlights
  - 4.1.1.1. Pills
  - 4.1.1.2. Sprays
  - 4.1.1.3. Others
4.2. Global Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacies
  - 4.2.1.2. Online Pharmacies
  - 4.2.1.3. Drug Stores
4.3. Global Non-injectable Insulin Market Outlook, by Region, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 4.3.1. Key Highlights
  - 4.3.1.1. North America
  - 4.3.1.2. Europe
  - 4.3.1.3. Asia Pacific
  - 4.3.1.4. Latin America
  - 4.3.1.5. Middle East & Africa

5. North America Non-injectable Insulin Market Outlook, 2019 - 2032

5.1. North America Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.1.1. Key Highlights
  - 5.1.1.1. Pills
  - 5.1.1.2. Sprays
  - 5.1.1.3. Others
5.2. North America Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacies
  - 5.2.1.2. Online Pharmacies
  - 5.2.1.3. Drug Stores
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America Non-injectable Insulin Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.3.1. Key Highlights
  - 5.3.1.1. U.S. Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.3.1.2. U.S. Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.3.1.3. Canada Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 5.3.1.4. Canada Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Non-injectable Insulin Market Outlook, 2019 - 2032

6.1. Europe Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.1.1. Key Highlights
  - 6.1.1.1. Pills
  - 6.1.1.2. Sprays
  - 6.1.1.3. Others
6.2. Europe Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacies
  - 6.2.1.2. Online Pharmacies
  - 6.2.1.3. Drug Stores
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe Non-injectable Insulin Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.3.1. Key Highlights
  - 6.3.1.1. Germany Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.2. Germany Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.3. U.K. Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.4. U.K. Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.5. France Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.6. France Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.7. Italy Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.8. Italy Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.9. Turkey Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.10. Turkey Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.11. Russia Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.12. Russia Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.13. Rest of Europe Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 6.3.1.14. Rest of Europe Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Non-injectable Insulin Market Outlook, 2019 - 2032

7.1. Asia Pacific Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.1.1. Key Highlights
  - 7.1.1.1. Pills
  - 7.1.1.2. Sprays
  - 7.1.1.3. Others
7.2. Asia Pacific Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospital Pharmacies
  - 7.2.1.2. Online Pharmacies
  - 7.2.1.3. Drug Stores
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific Non-injectable Insulin Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.3.1. Key Highlights
  - 7.3.1.1. China Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.2. China Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.3. Japan Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.4. Japan Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.5. South Korea Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.6. South Korea Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.7. India Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.8. India Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.9. Southeast Asia Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.10. Southeast Asia Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.11. Rest of Asia Pacific Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 7.3.1.12. Rest of Asia Pacific Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Non-injectable Insulin Market Outlook, 2019 - 2032

8.1. Latin America Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.1.1. Key Highlights
  - 8.1.1.1. Pills
  - 8.1.1.2. Sprays
  - 8.1.1.3. Others
8.2. Latin America Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacies
  - 8.2.1.2. Online Pharmacies
  - 8.2.1.3. Drug Stores
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Latin America Non-injectable Insulin Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.3.1. Key Highlights
  - 8.3.1.1. Brazil Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.2. Brazil Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.3. Mexico Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.4. Mexico Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.5. Argentina Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.6. Argentina Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.7. Rest of Latin America Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 8.3.1.8. Rest of Latin America Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Non-injectable Insulin Market Outlook, 2019 - 2032

9.1. Middle East & Africa Non-injectable Insulin Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.1.1. Key Highlights
  - 9.1.1.1. Pills
  - 9.1.1.2. Sprays
  - 9.1.1.3. Others
9.2. Middle East & Africa Non-injectable Insulin Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.2.1. Key Highlights
  - 9.2.1.1. Hospital Pharmacies
  - 9.2.1.2. Online Pharmacies
  - 9.2.1.3. Drug Stores
- 9.2.2. BPS Analysis/Market Attractiveness Analysis
9.3. Middle East & Africa Non-injectable Insulin Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.3.1. Key Highlights
  - 9.3.1.1. GCC Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.2. GCC Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.3. South Africa Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.4. South Africa Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.5. Egypt Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.6. Egypt Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.7. Nigeria Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.8. Nigeria Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.9. Rest of Middle East & Africa Non-injectable Insulin Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
  - 9.3.1.10. Rest of Middle East & Africa Non-injectable Insulin Market by Distribution Channel, Value (US$ Bn) and Volume (Units), 2019 - 2032
- 9.3.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

10.1. Company Market Share Analysis, 2024
10.2. Competitive Dashboard
10.3. Company Profiles
- 10.3.1. Novo Nordisk
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Product Portfolio
  - 10.3.1.3. Financial Overview
  - 10.3.1.4. Business Strategies and Development
- 10.3.2. Sanofi
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Product Portfolio
  - 10.3.2.3. Financial Overview
  - 10.3.2.4. Business Strategies and Development
- 10.3.3. Eli Lilly
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Product Portfolio
  - 10.3.3.3. Financial Overview
  - 10.3.3.4. Business Strategies and Development
- 10.3.4. MannKind Corporation
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Product Portfolio
  - 10.3.4.3. Financial Overview
  - 10.3.4.4. Business Strategies and Development
- 10.3.5. Biocon
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Product Portfolio
  - 10.3.5.3. Financial Overview
  - 10.3.5.4. Business Strategies and Development
- 10.3.6. Janssen Pharmaceuticals
  - 10.3.6.1. Company Overview
  - 10.3.6.2. Product Portfolio
  - 10.3.6.3. Financial Overview
  - 10.3.6.4. Business Strategies and Development
- 10.3.7. Adocia
  - 10.3.7.1. Company Overview
  - 10.3.7.2. Product Portfolio
  - 10.3.7.3. Financial Overview
  - 10.3.7.4. Business Strategies and Development
- 10.3.8. Oramed Pharmaceuticals
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Product Portfolio
  - 10.3.8.3. Financial Overview
  - 10.3.8.4. Business Strategies and Development
- 10.3.9. Dance Biopharm
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Product Portfolio
  - 10.3.9.3. Financial Overview
  - 10.3.9.4. Business Strategies and Development
- 10.3.10. Medtronic
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Product Portfolio
  - 10.3.10.3. Financial Overview
  - 10.3.10.4. Business Strategies and Development
- 10.3.11. Verily Life Sciences
  - 10.3.11.1. Company Overview
  - 10.3.11.2. Product Portfolio
  - 10.3.11.3. Financial Overview
  - 10.3.11.4. Business Strategies and Development
- 10.3.12. Zafgen
  - 10.3.12.1. Company Overview
  - 10.3.12.2. Product Portfolio
  - 10.3.12.3. Financial Overview
  - 10.3.12.4. Business Strategies and Development
- 10.3.13. Dance Biopharm
  - 10.3.13.1. Company Overview
  - 10.3.13.2. Product Portfolio
  - 10.3.13.3. Financial Overview
  - 10.3.13.4. Business Strategies and Development
- 10.3.14. Senseonics
  - 10.3.14.1. Company Overview
  - 10.3.14.2. Product Portfolio
  - 10.3.14.3. Financial Overview
  - 10.3.14.4. Business Strategies and Development
- 10.3.15. Bigfoot Biomedical
  - 10.3.15.1. Company Overview
  - 10.3.15.2. Product Portfolio
  - 10.3.15.3. Financial Overview
  - 10.3.15.4. Business Strategies and Development

11. Appendix

11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations